A study from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, reveals how two genetic mutations, IDH2 and SRSF2, cooperate to erroneously splice RNA messages and disrupt the cell’s identity.
A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv University, found a mechanism that allows breast cancer to send metastases to the brain. The findings could enable the development of new drugs and personalized monitoring for early detection and treatment of brain metastases.
Fred Hutch Cancer Center researchers developed a new tool that enables anyone to immediately assess their colorectal cancer risk online. Called MyGeneRisk, the free, web-based calculator allows users to input basic health information, including lifestyle habits and genetic data, to estimate their risk.
A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery.
FDA approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously administered therapy for patients with epidermal growth factor receptor-mutated non-small cell lung cancer.
FDA granted breakthrough therapy designation to Enhertu (trastuzumab deruxtecan) for adult patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence.
The China National Medical Products Administration approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Dark Blue Therapeutics was acquired by Amgen.
Niowave Inc. and AstraZeneca are expanding their existing supply agreement to a 10-year commitment to deliver actinium-225, following AstraZeneca’s decision to exercise its option to increase capacity.
Kallisio has collaborated with Stanford Health Care to support the clinical implementation of its FDA-cleared Stentra system for use in head-and-neck cancer radiation therapy.
